Subscriber access provided by UNIVERSITY OF ADELAIDE LIBRARIES
Article
Poloxamer-decorated polymer nanoparticles for lung surfactant compatibility Moritz Beck-Broichsitter, Adam Bohr, and Christian Arnold Ruge Mol. Pharmaceutics, Just Accepted Manuscript • DOI: 10.1021/acs.molpharmaceut.7b00477 • Publication Date (Web): 16 Aug 2017 Downloaded from http://pubs.acs.org on August 23, 2017
Just Accepted “Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.
Molecular Pharmaceutics is published by the American Chemical Society. 1155 Sixteenth Street N.W., Washington, DC 20036 Published by American Chemical Society. Copyright © American Chemical Society. However, no copyright claim is made to original U.S. Government works, or works produced by employees of any Commonwealth realm Crown government in the course of their duties.
Page 1 of 36
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Molecular Pharmaceutics
Poloxamer-decorated polymer nanoparticles for lung surfactant compatibility Moritz Beck-Broichsitter1,2,3,*, Adam Bohr2,4 and Christian A. Ruge2 1
Medical Clinic II, Department of Internal Medicine, Justus-Liebig-Universität, Giessen, Germany 2 3
Institut Galien, Faculté de Pharmacie, Université Paris-Sud XI, Châtenay-Malabry, France
Present address: Chemical and Pharmaceutical Development, Bayer AG, Wuppertal, Germany 4
Department of Pharmacy, University of Copenhagen, Copenhagen, Denmark
* Corresponding author: Moritz Beck-Broichsitter, Ph.D.; Chemical and Pharmaceutical Development, Bayer AG, Friedrich-Ebert-Strasse 217-333 D-42117 Wuppertal, Germany Tel.: 0049 214 3000 Fax: 0049 202 36 3867 E-mail:
[email protected] Conflict of interest: The authors disclose that no conflicting interests associated with the manuscript exist. Submission declaration: All authors have contributed to the conception and design of the study and acquisition, analysis and interpretation of data. All authors have drafted the article and revised it critically for important intellectual content. All authors have approved the final article. The authors certify that this manuscript, or any part of it, has not been published and will not be submitted elsewhere for publication while being considered by Molecular Pharmaceutics. Role of funding source: The “Deutsche Forschungsgemeinschaft” (BE 5308/1-1 and RU 1866/1-2), “Wirtschafts- und Infrastrukturbank Hessen” (Nanosurfact) and the Danish Council for Independent Research (DFF-12-131927) provided financial support for the conduct of the research. The funding sources had no involvement in the study design; in the collection, analysis and interpretation of data; in the writing of the report; or in the decision to submit the article for publication.
Abstract Lung-delivered polymer nanoparticles provoked dysfunction of the essential lung surfactant system. A steric shielding of the nanoparticle surface with poloxamers could minimize the unwanted interference of polymer nanoparticles with the biophysical function of lung surfactant.
ACS Paragon Plus Environment
1
Molecular Pharmaceutics
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Page 2 of 36
The extent of poly(styrene) and poly(lactide) nanoparticle-induced lung surfactant inhibition could be related to the type and content of the applied poloxamer. Escalations of the adsorbed coating layer thickness (>3 nm) as well as concentration (brush- rather than mushroom-like conformation of poly(ethylene glycol), chain-to-chain distance of
